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Infections caused by multidrug-resistant Pseudomonas aeruginosa in hospitalized
patients are often fatal, and nosocomial infections caused by Guiana extended-
spectrum (GES) β-lactamase-producing strains are of growing concern. Several
genotypes of the GES β-lactamase gene (blaGES) include a single missense mutation,
a change from G to A at nucleotide position 493 (G493A) that changes glycine to serine;
the mutant enzyme exhibits carbapenemase activity. Rapid and reliable identification
of drug-resistance is important in clinical settings; however, culture methods remain
the gold standard. Conventional and real-time PCR cannot identify carbapenemase-
producing genotypes, and direct DNA sequencing is essential. We established a novel
loop-mediated isothermal amplification (LAMP) method to detect various genotypes
of blaGES and another LAMP method to discriminate carbapenemase genotypes of
blaGES. We evaluated the two assays using clinical P. aeruginosa strains. Two primer
sets targeting blaGES (GES-LAMP) and the point mutation (Carba-GES-LAMP) were
designed and evaluated for specificity and sensitivity. The detection limit of the GES-
LAMP method was assessed using purified DNA and DNA-spiked clinical samples
(urine, sputum, and blood). To determine the clinical usefulness of the methods, we used
different (genotypically and phenotypically) P. aeruginosa clinical isolates, collected
from diverse geographical locations between 2003 and 2012. The novel LAMP assay
targeting blaGES was highly specific. The detection limit was 10 DNA copies per reaction;
the assay was 10-fold more sensitive than conventional PCR. The LAMP assay detected
blaGES with high sensitivity in all DNA-spiked samples; PCR did not detect blaGES in
blood samples. The GES-LAMP method correctly detected the 5 isolates containing
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blaGES among the 14 isolates tested. Using these isolates, we confirmed that our Carba-
GES-LAMP method of detecting point mutations correctly identified the two blaGES
positive organisms with carbapenemase activity. To the best of our knowledge, this is
the first report of the GES β-lactamase gene detection assay using the LAMP method.
Our new assays effectively detect blaGES and critical unique mutations.
Keywords: blaGES, β-lactamase, point mutation, carbapenemase, loop-mediated isothermal amplification,
Pseudomonas aeruginosa
INTRODUCTION
Multidrug-resistant bacteria have spread worldwide and become
a major clinical concern and public health issue as well. Invasive
infection by Pseudomonas aeruginosa is often fatal in the absence
of appropriate antibiotic treatment (Miyoshi-Akiyama et al.,
2017). As β-lactamase genes are plasmid-borne, a failure to
treat drug-resistant bacteria may trigger nosocomial infections.
Of the various β-lactamase genes, Guiana extended-spectrum
(GES) β-lactamase has become of increasing concern (Poirel
et al., 2012). GES was first described in 2000 in French Guiana
(Poirel et al., 2000) and is an Amber class A extended-spectrum
β-lactamase. However, certain variants (GES-4, -5, -6, -14, -15,
-16, -18, -20, and -24) feature a single missense mutation at
nucleotide position 493 (G493A) that changes glycine 165 to
serine (Gly165Ser), which was previously reported as Gly170Ser
(Bebrone et al., 2013). The resulting mutant enzyme exhibits
carbapenemase activity (Bonnin et al., 2017). In Japan, GES-
4 and GES-5 carbapenemase-producing P. aeruginosa have
caused severe hospital-acquired infections (Kanayama et al.,
2016; Yamasaki et al., 2017). Reports of GES-type enzymes remain
rare but are steadily increasing (Naas et al., 2016).
Rapid and reliable identification of drug-resistance is essential
to ensure that antibiotic use is appropriate. Conventional
culture remains the gold standard for assessing antibiotic
resistance despite being time-consuming, requiring sophisticated
laboratory equipment and quality-control, and yielding
ambiguous outcomes. Furthermore, the number of inoculated
bacteria affect the drug minimum inhibitory concentration
(MIC) (Bratu et al., 2005). Conventional PCR-based assays can
detect β-lactamase genes but require well-equipped laboratories.
Moreover, neither conventional PCR nor real-time PCR can
identify carbapenemase-producing genotypes, and direct DNA
sequencing is essential to do so (de Oliveira et al., 2017).
Loop-mediated isothermal amplification (LAMP) methods
are becoming increasingly popular due to their relative simplicity
and accuracy. The unique priming mechanism allows rapid
and specific DNA amplification (Notomi et al., 2000), with
no requirement for expensive equipment or a sophisticated
laboratory. LAMP is a convenient and inexpensive alternative
to PCR in terms of point-of-care testing (POCT). Here,
we established two LAMP methods to detect the GES
β-lactamase gene (blaGES, GES-LAMP) and carbapenemase
genotypes (Carba-GES-LAMP) and applied the two assays to
evaluate characterized (both genotypically and phenotypically)
clinical P. aeruginosa strains from diverse geographical locations
collected between 2003 and 2012 (Kos et al., 2015).
MATERIALS AND METHODS
Bacterial Strains
A total of 22 bacterial strains including 8 standard strains
(Table 1) and 14 clinical P. aeruginosa strains (Table 2) were
used to evaluate the LAMP methods. The eight standard
strains included six kinds of genotypes of β-lactamase producers
(KPC, NDM, VIM, IMP, OXA, and GES): two Klebsiella
pneumoniae, one Escherichia coli, four P. aeruginosa, and one
Acinetobacter bereziniae provided by AstraZeneca (Waltham,
MA, United States). Genomic DNA was extracted using the
Maxwell 16-cell DNA purification kit (Promega, Madison,
WI, United States). DNA concentrations were measured
using the NanoDrop 1000 (Thermo Fisher Scientific Inc.,
Waltham, MA, United States). Genome copy numbers were
calculated based on genome sizes of 6.5 Mbp for P. aeruginosa
(PB369; GenBank accession number, CP025049.1), 5.4 Mbp
for K. pneumoniae (Kp52.145; GenBank accession number,
FO834906.1), 5.2 Mbp for E. coli (CFT073; GenBank accession
number, AE014075.1), and 4.5 Mbp for A. bereziniae (XH901;
GenBank accession number, NZ_CP018259.1). Each DNA
sample was normalized to the same concentration and used to
evaluate assay specificity. To validate blaGES detection limits, we
used genomic DNA from the P. aeruginosa strain ARC3917.
Serial 10-fold-diluted DNA samples (105, 104, 103, 102, 10,
and 1 genome copies) were amplified by LAMP and the
results were compared with those from PCR assays. To confirm
reproducibility, triplicate tests were performed over a 3-day
period.
TABLE 1 | Reactivities and specificities of PCR and LAMP assays detecting
blaGES.
Strain ID Species Genotype PCRa GES-LAMPb
ARC2780 Acinetobacter bereziniae IMP-1 (−)c (−)
ARC2945 Klebsiella pneumoniae KPC-2 (−) (−)
ARC3471 Pseudomonas aeruginosa VIM-2 (−) (−)
ARC3475 Pseudomonas aeruginosa OXA-48 (−) (−)
ARC3600 Escherichia coli NDM-1 (−) (−)
ARC3802 Klebsiella pneumoniae NDM-1 (−) (−)
ARC3917 Pseudomonas aeruginosa GES-1 (+) (+)
ARC3936 Pseudomonas aeruginosa VIM-7 (−) (−)
aPCR results obtained via electrophoretic analysis; bLAMP results determined via
Loopamp real-time turbidimetry and the naked eye. c (-), negative; (+), positive.
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TABLE 2 | Clinical Pseudomonas aeruginosa isolates evaluated.
Strain no. Origin of isolate Genotype Meropenem Assays
Country Anatomical site MIC (mg/L) PCR GES-LAMP Carba-GES-LAMP
GES β-lactamase-producing strains
AZPAE14831 Argentina RTIa GES-1 0.5 (S)d (+) (+) (−)
AZPAE14948 Argentina IAIb GES-5 >32 (R) (+) (+) (+)
AZPAE13856 India Unknown GES-7 0.5 (S) (+) (+) (−)
AZPAE13848 India Unknown GES-9 0.25 (S) (+) (+) (−)
AZPAE13880 Mexico Unknown OXA-2, GES-19, GES-20-like >32 (R) (+) (+) (+)
Other β-lactamase-producing strains
AZPAE13872 Mexico Unknown IMP-15 >32 (R) (−) (−) (−)
AZPAE13879 Argentina Unknown VIM-11, OXA-17 16 (R) (−) (−) (−)
AZPAE14688 Mexico Unknown IMP-18 >32 (R) (−) (−) (−)
AZPAE14719 Colombia RTI KPC-2 >32 (R) (−) (−) (−)
AZPAE14720 Colombia UTIc OXA-2, KPC-2 >32 (R) (−) (−) (−)
AZPAE14822 Brazil IAI OXA-56 8 (R) (−) (−) (−)
AZPAE14862 India UTI IMP-13 2 (S) (−) (−) (−)
AZPAE14900 India IAI OXA-10, VEB-like, VIM-5 16 (R) (−) (−) (−)
AZPAE15029 France RTI VIM-2, OXA-4 >32 (R) (−) (−) (−)
aRespiratory tract infections; bUrinary tract infections, c Intra-abdominal infections. d (S), susceptible; (R), resistant.
Clinical P. aeruginosa Strains
Fourteen clinical P. aeruginosa strains including five blaGES
segments (GES-1, -5, -7, -9, and -19/20-like) were randomly
selected from 388 strains with previously reported genotypes
and phenotypes (Kos et al., 2015; Table 2) isolated from
diverse geographical locations (Colombia, India, Spain, France,
Greece, Germany, Argentina, Croatia, China, Brazil, Mexico,
and the Philippines) between 2003 and 2012. Genomic DNA
was extracted using the Maxwell 16-cell DNA purification
kit (Promega). Whole-genome sequences were analyzed using
the HiSeq 2000 or MiSeq platforms (Illumina, San Diego,
CA, United States). Susceptibility to meropenem was explored
using frozen Trek-Sensititre custom plates (Thermo Fisher
Scientific Inc.) following the guidelines of the Clinical and
Laboratory Standards Institute (2012). The results of meropenem
MIC are listed in Table 2. We used genomic DNA from
P. aeruginosa strain AZPAE4948 to evaluate the LAMP
assay.
LAMP Primer Design
We targeted the blaGES gene (GES-1; GenBank accession number,
AF355189.1; Supplementary Figure S1) using primers designed
by Primer Explore V5 software (FUJITSU, 2016). The LAMP
primers included two outer primers (F3 and B3), a forward
inner primer (FIP), a backward inner primer (BIP), and loop
primers (LF and LB) (Table 3). In addition, we developed primers
targeting the G493A mutation of blaGES (GES-5; GenBank
accession number, EF190326.1; Supplementary Figure S1) using
an amplification-refractory mutation system (ARMS) (Newton
et al., 1989; Ikeda et al., 2007). The BIP featured the addition of a
single nucleotide mutation to the 5′-end, followed by the addition
of two mutations in the second (G to C) and fifth (A to T)
positions from the 5′ end. Other primers were designed using
Primer Explorer V5 software (Table 3).
LAMP
The LAMP reaction mixture (25 µL) contained 1.6 µM
FIP and BIP each, 0.2 µM F3 and B3 each, 0.4 µM LF,
8 U Bst DNA polymerase (large fragment) (New England
TABLE 3 | LAMP primer sets used for genotypic identification of blaGES and the
single missense mutation (G493A) that changes glycine 165 to a serine, endowing
the enzyme with carbapenemase activity.
Sequence 5′–3′
GES-LAMP primer
GES_F3 ACC ATT GAG AGG TGG CTG AT
GES_B3 TGA CCG ACA GAG GCA ACT
GES_FIP GTT GGC GCA GGT ACC AGT TTT CCG
ACA CTA CGA GCG GGT T
GES_BIP GCC CAG GAG AGA GAT TAC GCT GAT
TCG TCA CGT TCT ACG GC
GES_LF TCT CCA ACA ACC CAA TCT TTA GG
GES_LB GTG TAT ACA ACG GCC CCG A
Carba-GES-LAMP primer
Carba-GES_F3 TGC AGC TTA GCG ACA ATG G
Carba-GES_B3 CCG CCA TAG AGG ACT TTA GC
Carba-GES_FIP AGC CGA CTC ACA GAG TCG CCA GAG
AAA TTG GCG GAC CTG
Carba-GES_BIP AaCbC GTcC AAC ACA CCT GGC GAC
ACA GTA CGT GCC ATA GCA A
Carba-GES_LF CGA AAA TAC TGC GTC ATT GCA G
Carba-GES_LB CCT CAG AGA TAC AAC TAC GCC TA
aA single missense mutation (G493A) detected by ARMS; boriginal sequence G;
coriginal sequence A.
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Biolabs, Ipswich, MA, United States), 1.4 mM all four
deoxynucleoside triphosphates, 0.8 M betaine (Sigma, St. Louis,
MO, United States), 20 mM Tris–HCl (pH 8.8), 10 mM KCl,
10 mM (NH4)2SO4, 8 mM MgSO4, 0.1% (v/v) Tween 20, and
template DNA (2 µL). Each mixture was incubated at 63◦C
for 60 min and then heated at 80◦C for 2 min to terminate
the reaction. For the Carba-GES-LAMP assay, the incubation
time was 50 min. We monitored reaction tube turbidity in real
time using a Loopamp turbidimeter (EXIA; Eiken Chemical Co.,
Tokyo, Japan) to read the optical density at 650 nm (OD650) at
6-s intervals. We recorded the time required to exceed a turbidity
level of 0.1, in accordance with the manufacturer’s protocol.
Amplified products could be seen with the naked eye.
Analysis of LAMP Products
Amplified LAMP products were sequenced at the Akita
Prefectural University Biotechnology Center using the BigDye
Terminator V3.1 cycle sequencing kit (Applied Biosystems,
Foster City, CA, United States) on the 3130xL genetic analyzer
(Applied Biosystems). The following F2 primers for GES-LAMP
and Carba-GES-LAMP were used to sequence the target regions;
GES-F2, 5′-TTC TAG CAT CGG GAC ACA TG-3′ and Carba-
GES-F2, 5′-AGA GAA ATT GGC GGA CCT G-3′, respectively.
PCR
blaGES genes were amplified by PCR using previously described
primers: GES-F, 5′-CTA TTA CTG GCA GGG ATC G-3′; GES-R,
5′-CCT CTC AAT GGT GTG GGT-3′ (Monteiro et al., 2012).
PCR assays were performed using the Ex Taq enzyme (Takara Bio,
Tokyo, Japan) in a 25 µL reaction mixture containing 0.2 mM
each deoxyribonucleoside triphosphate, 10 mM Tris–HCl buffer
(pH 8.3), 50 mM KCl, 2 mM MgCl2, 0.5 µM each primer, 1
U Ex Taq DNA polymerase, and template DNA (2 µL). The
PCR program sequence was 94◦C for 1 min, followed by 30
cycles of denaturation at 94◦C for 30 s, annealing at 55◦C for
30 s, and extension at 72◦C for 60 s, and a final extension at
72◦C for 15 min, followed by storage at 4◦C. All reactions were
performed in duplicate using the Veriti thermal cycler (Applied
Biosystems). The resulting PCR products were subjected to
agarose gel electrophoresis followed by staining with ethidium
bromide. The expected size of the DNA fragment is 594 bp.
DNA-Spiked Specimens
To analyze the effects of biological substances on the established
LAMP amplification, we studied the sensitivity of the LAMP
assay using DNA-spiked clinical samples. We collected urine
and blood specimens from five healthy volunteers in Nihon
University School of Medicine. The blood specimens were
heparinised and stored at −80◦C. Sputum specimens were
obtained from seven patients of the Ageo Central General
Hospital and frozen at −80◦C to inactivate bacteria. After
approval was granted by the Biosafety Committee of Nihon
University, the specimens were handled using the risk group 2
protocol of the laboratory biosafety manual of the World Health
Organization, Geneva, 2004 (World Health Organization, 2004).
Urine specimens were boiled at 95◦C for 5 min and then
centrifuged at 1,500 rpm. Blood and sputum samples were
subjected to a LoopampTM PURE DNA extraction kit (Eiken
Chemical Co.) according to the manufacturer’s instructions.
Purified blaGES DNA (from P. aeruginosa ARC3917) was spiked
into the specimens and used to determine the detection limits of
the GES-LAMP and PCR assays.
Ethics Statement
We utilized urine and blood specimens from five healthy
volunteers in Nihon University School of Medicine. The study
protocol was reviewed and approved by the Institutional
Review Board of Nihon University School of Medicine (IRB
# 28-9-0). Written informed consent was obtained from five
healthy volunteers. Using the IRB approved protocol, seven
patient sputum specimens (Ageo Central General Hospital) were
collected in accordance with the recommendations of the Japan
Society of Clinical Examination Medicine that supports “the
use of specimens that have completed clinical tests for work,
education, research.” This guidance provides access to specimens
when it is difficult to obtain consent, the sample is anonymized,
and where the scientific/ethical review committee (i.e., IRB)
has approved the study protocol. Written consent was waived
because specimens were anonymized discarded samples from the
hospital clinical laboratory. The ethical approval for collection
of those specimens were obtained from the ethical committee
at the Ageo Central General Hospital (Approval # 434) and
the Institutional Review Board of Nihon University School of
Medicine (Approval # 28-9-0).
RESULTS
Analytical Reactivity and Specificity of
the GES-LAMP Assay
The LAMP assay successfully amplified the target sequence,
as confirmed by visually evident turbidity in the reaction
tube and by real-time turbidimetry (Figure 1). Of the various
β-lactamase genes, the assay detected only blaGES (Table 1). The
product was subjected to direct sequencing. The sequences were
compared with those of the targeted region (bases 337–425) of
the GES-1 gene (from F1 to B1c, Supplementary Figure S1A).
The sequences obtained were identical to those expected
(Supplementary Figure S2A).
Detection Limits
The detection limit of the GES-LAMP assay was 10 DNA copies
per reaction, and that of the PCR assay was 100 copies. The
LAMP assay was thus highly sensitive, 10-fold more so than PCR.
LAMP products were measurable turbidimetrically in real-time
and were evident with the naked eye. No false-positive reactions
were observed.
DNA-Spiked Specimens
Assay detection limits were determined using DNA-spiked blood,
urine, and sputum. The GES-LAMP detection limits were 10
DNA copies per reaction, thus identical to that reported above
(Table 4). The PCR detection limits were 100 DNA copies for the
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FIGURE 1 | blaGES LAMP assay data derived via real-time turbidimetry. Serial 10-fold-diluted samples (105, 104, 103, 102, 10, and 1 DNA copies) were assayed by
LAMP. The detection limit was 10 DNA copies.
DNA-spiked urine and sputum specimens, again identical to that
reported above. However, the detection limit was >105 copies in
DNA-spiked blood specimens (Table 4).
Evaluation Using Clinical Strains
Using the 14 clinical P. aeruginosa strains, the GES-LAMP
assay amplified the five blaGES segments (GES-1, -5, -7, -9, and
-19/20-like; Table 2), and no other genotype. The results were
thus identical to those of PCR (Table 2 and Supplementary
Figure S3).
Carba-GES-LAMP Assay
Of the five blaGES-positive samples, only GES-5 and -19/20-like
β-lactamase-producing isolates exhibited carbapenem resistance
(Table 2), consistent with their genotypes. Our Carba-GES-
LAMP assay detected only GES-5 and -19/20-like alleles
containing the blaGES Gly165Ser missense mutation. Using the
ARMS, we successfully designed the Carba-GES-LAMP primers
that distinguish the GES variants. The detection limit of the
Carba-GES-LAMP assay was 104 DNA copies. No amplification
TABLE 4 | Detection limits of the PCR and LAMP assays used to detect DNA from
P. aeruginosa of genotype blaGES in DNA-spiked specimens.
Detection limit
PCR GES-LAMP





aAmount of DNA per reaction; bSupernatant data obtained after boiling and
centrifugation; cSamples prepared via LoopampTM PURE DNA extraction kit (Eiken
Chemical Co.).
of non-carbapenemase-producing blaGES genotypes (GES-1, -7,
and -9) or any other genotype was evident within 50 min. The
product was subjected to direct sequencing. The sequences were
compared with those of the targeted region (bases 450–512) of
the GES-5 gene (from F1 to B1c, Supplementary Figure S1B).
The five base pairs of 3′ end of B1c region were matching
to the Carba-GES-LAMP primer sequences (ACCGT; 493-497,
Supplementary Figure S1B) including two mutations (Table 3)
and obtained other sequences were identical to those expected
(Supplementary Figure S2B).
DISCUSSION
We established a novel LAMP assay detecting blaGES. Because
β-lactamase genes spread widely via plasmids, rapid and accurate
POCT drug-resistance assessment is imperative. Our blaGES
LAMP assay was highly specific and more sensitive than PCR.
blaGES was correctly identified in 14 clinical isolates expressing
various β-lactamases. LAMP reactions are not inhibited by
contaminants in DNA-spiked samples. On the other hand, PCR
reactions are inhibited by such contaminants, especially heparin
(Satsangi et al., 1994), and other blood components including
heme, leukocyte DNA, and immunoglobulin G; such inhibitors
must be removed prior to PCR (Al-Soud et al., 2000; Al-
Soud and Radstrom, 2001). We used the LoopampTM PURE
DNA extraction kit (Eiken Chemical Co.) to extract DNA
over 30 min, and centrifugation was not required. LAMP can
thus be performed at the bedside. We then sought to detect
the G493A mutation. GES β-lactamases hydrolyse oxyimino-
cephalosporins and those with the Gly165Ser mutation exhibit
carbapenemase activity (Naas et al., 2016). P. aeruginosa blaGES
strains may cause fatal nosocomial diseases. An outbreak of
GES-5 β-lactamase-producing P. aeruginosa was reported in
a long-term Japanese care facility (Kanayama et al., 2016).
We designed GES-type carbapenemase-specific primers via
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ARMS, first demonstrated in 1989 (Newton et al., 1989) to detect
any mutation via PCR. In 2007, Ikeda et al. used ARMS to
design LAMP primers and detected a point mutation predicting
the effects of the anti-lung cancer drug gefitinib (Ikeda et al.,
2007). We previously used ARMS to establish a LAMP assay that
distinguished Neisseria meningitidis serogroup Y from serogroup
W (Lee et al., 2015). Here, we used ARMS to design the BIP,
avoiding amplification of the wild-type gene. LAMP may be
useful to detect GES-type carbapenemase genes.
CONCLUSION
We established a novel LAMP assay for blaGES with a comparable
specificity and greater sensitivity to those of PCR. LAMP assays
do not require substrate purification and are appropriate for
POCT. LAMP can be used to detect GES-type carbapenemase
genes with missense mutations. Further work involving more
clinical specimens is required.
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